Effectiveness of a 2-year Menopause Medicine Curriculum for Obstetrics and Gynecology Residents
Overview
Affiliations
Objective: Previous work has shown American obstetrics and gynecology (OB/GYN) residents are lacking in menopause training. Our objective was to assess the effectiveness of a 2-year menopause medicine curriculum in improving OB/GYN residents' knowledge and self-assessed competency in menopause topics.
Methods: We developed a menopause medicine-teaching curriculum for OB/GYN residents at our academic hospital-based residency program. The 2-year curriculum was composed of year 1: four 1-hour lectures and one 2-hour lab with cases presentations, and year 2: three 1-hour lectures and one 2-hour lab. Core topics included menopause physiology, hormone therapy, breast health, bone health, cardiovascular disease, and autoimmune disease. Pre- and posttests assessed resident knowledge and comfort in core topics, and a pre- and postcurriculum survey assessed utility and learning satisfaction.
Results: From July 2011 to June 2013, 34 OB/GYN residents completed the menopause curriculum annually with an average attendance at each module of 23 residents. Pre-/posttest scores improved from a mean pretest score of 57.3% to a mean posttest score of 78.7% (P < 0.05). Before the curriculum, most residents did not feel comfortable managing menopause patients with 75.8% reporting feeling "barely comfortable" and 8.4% feeling "not at all comfortable." After the 2-year curriculum, 85.7% reported feeling "comfortable/very comfortable" taking care of menopause patients. The majority of residents (95.2%) reported the menopause curriculum was "extremely useful."
Conclusions: A 2-year menopause medicine curriculum for OB/GYN residents utilizing lectures and a lab with case studies is an effective modality to improve resident knowledge required to manage menopause patients.
Adreak N, Mackay M, Pike A, ONeill C, Sterling E, Randhawa V CJC Open. 2024; 6(2Part B):463-472.
PMID: 38487051 PMC: 10935693. DOI: 10.1016/j.cjco.2023.11.001.
Harper J, Phillips S, Biswakarma R, Yasmin E, Saridogan E, Radhakrishnan S Womens Health (Lond). 2022; 18:17455057221106890.
PMID: 35758176 PMC: 9244939. DOI: 10.1177/17455057221106890.
Differences in patient-reported hormone therapy use for menopause symptoms by provider specialty.
McCarty M, Thomas H Climacteric. 2021; 24(6):600-604.
PMID: 34236012 PMC: 9827593. DOI: 10.1080/13697137.2021.1945026.
Meinema J, Buwalda N, van Etten-Jamaludin F, Visser M, van Dijk N Acad Med. 2018; 94(2):281-290.
PMID: 30157087 PMC: 6365274. DOI: 10.1097/ACM.0000000000002428.
What the Women's Health Initiative has taught us about menopausal hormone therapy.
Chester R, Kling J, Manson J Clin Cardiol. 2018; 41(2):247-252.
PMID: 29493798 PMC: 6490107. DOI: 10.1002/clc.22891.